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Aims: To ensure the integrity of the planned analyses and maximize the clinical utility
of the VERIFY study results by describing the detailed concepts behind its statistical
analysis plan (SAP) before completion of data collection and study database lock. The
SAP will be adhered to for the final primary data analysis of the VERIFY trial.
Materials and Methods: Vildagliptin efficacy in combination with metformin for early
treatment of T2DM (VERIFY) is an ongoing, multicentre, randomized controlled trial
aiming to demonstrate the clinical benefits of glycaemic durability and glucose con-
trol achieved with an early combination therapy in newly-diagnosed type 2 diabetes
(T2DM) patients.
Results: The SAP was initially designed at the study protocol conception phase and
later modified, as reported here, in collaboration between the steering committee
members, statisticians, and the VERIFY study leadership team. All authors were
blinded to treatment allocation. An independent statistician has additionally retrieved
and presented unblinded data to the independent data safety monitoring committee.
An overview of the trial design with a focus on describing the fine-tuning of the anal-
ysis plan for the primary efficacy endpoint, risk of initial treatment failure, and sec-
ondary, exploratory and pre-specified subgroup analyses is provided here.
Conclusion: According to optimal trial practice, the details of the statistical analysis
and data-handling plan prior to locking the database are reported here. The SAP
accords with high-quality standards of internal validity to minimize analysis bias and
will enhance the utility of the reported results for improved outcomes in the manage-
ment of T2DM.
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1 | INTRODUCTION
The UK Prospective Diabetes Study was the first pivotal study that
formed and defined a paradigm for expectations concerning therapeu-
tic management of hyperglycaemia in individuals with newly diag-
nosed diabetes.1 The study demonstrated positive microvascular
outcomes with intensive glucose control policies as compared with
conventional glucose control policies, and demonstrated improved
outcomes in the subgroup of overweight patients receiving metfor-
min, including decreased myocardial infarction, as well as improve-
ments in diabetes-related endpoints and all-cause mortality.2
However, the UK Prospective Diabetes Study relied on a stepwise
approach based on metformin, sulfonylureas and insulin treatment.
After completion of the study, new glucose-lowering agents that may
offer more suitable early intensive treatment for individuals with type
2 diabetes mellitus (T2DM) have been introduced.
During the last decade, dipeptidyl peptidase-4 (DPP-4) inhibitors
have been shown in various diverse populations,3-6 in innovative ran-
domized clinical trials7 and also in non-interventional real-world
studies,8 to maintain improved glycaemic control without
hypoglycaemia. Because of their main effect on the pancreatic islet
cells, they have been recognized as ideal adjuncts to an insulin sensi-
tizer such as metformin for an effective early treatment approach.9
This allows the current treatment paradigm, which is characterized by
ineffective lifestyle interventions, followed by monotherapy, which is
often delayed, and the frequently prolonged periods of sustained
hyperglycaemia that have become inevitable consequences of
sequential clinical inertia, to be overcome.10 Thus, it is appropriate to
examine the role of a more intensive and effective initial therapy.
The VERIFY study was designed to investigate the long-term clini-
cal benefits of early treatment intensification with a DPP-4 inhibitor
(vildagliptin)-metformin combination over standard-of-care metformin
monotherapy in maintaining durable glycaemic control in individuals
with newly or recently diagnosed T2DM.11 We hypothesized that a
proactive approach of initiating early treatment with a pat-
hophysiologically synergistic combination would increase the durabil-
ity of glycaemic control as compared to a policy of prescribing
metformin alone, followed by a second-line agent such as vildagliptin,
only at the time of glycaemic deterioration.12
In contrast to many completed and ongoing cardiovascular
(CV) outcome studies in those with established CV disease and/or mul-
tiple risk factors and long disease duration,13 we aimed to recruit a rep-
resentative diverse population reflecting the current characteristics of
newly diagnosed persons at low CV risk. However, changes in the land-
scape of trials with an extensive focus on CV safety and some of the
unexpected safety findings indicating increased risk of hospitalizations
for heart failure (hHF) with saxagliptin in the SAVOR-TIMI trial,14 led to
an amendment to the VERIFY study protocol, stipulating now the inclu-
sion of a CV adjudication committee and an unblinded independent
data monitoring committee. Nevertheless, there have been no early
indicators of unexpected or new safety findings during the study since
2012 or in any other populations with vildagliptin based on a recent
holistic safety assessment exploring pharmacovigilance reports15 or
real-world evidence in diverse populations.3,15
2 | STUDY DESIGN
2.1 | Introducing the concept of early combination
The VERIFY study (Vildagliptin efficacy in combination with metfor-
min for early treatment of T2DM; NCT01528254) is the first long-
term study to address the concept of an early, initial combination
treatment paradigm for T2DM. It is an ongoing, five-year, multina-
tional, multi-ethnic study and the pragmatic study design and primary
statistical assumptions have been described in detail in a previous
publication.11 The study comprises three treatment periods (Figure 1).
During Period 1, patients were randomized to either early combina-
tion treatment with individualized doses of metformin (between 1 and
2 g/day) and vildagliptin (50 mg twice daily) or standard-of-care met-
formin monotherapy (+placebo). Randomization was performed using
an interactive response technology (IRT) system. If initial treatment
failed to maintain glycated haemoglobin (HbA1c) <7.0%, confirmed at
two consecutive scheduled study visits, vildagliptin was added to met-
formin during Period 2. During Period 3, rescue therapy with insulin
was acceptable for maintaining glycaemic control based on local
guidelines, at the discretion of the investigator. The protocol also pro-
vided the option of choosing another third-line treatment strategy,
leading to discontinuation from the study. The Period 3 start date is
defined as the date of insulin initiation.
Both patients and investigators remained masked to treatment
allocation during Period 1, and the study will compare the success of
these two different approaches to treatment. All treatments are
referred to as “treatment approach” throughout this statistical analysis
plan (SAP) to acknowledge that patients switched from one treatment
to another based on individualized response over the entire study
period.
The main inclusion and exclusion criteria have been published
previously.11 Recruitment for the VERIFY trial commenced in
March 2012 and, despite a narrow glycaemic range for inclusion, a
linear rate of randomization of eligible, newly diagnosed patients
worldwide was completed ahead of schedule in April 2014. The
enrolment phase indicated that an absence of aptitude within
healthcare systems, especially in developing countries, for identify-
ing individuals at risk of diabetes was the major reason for screen-
ing failure, with approximately 80% of cases having an HbA1c value
outside the protocol-defined, centrally assessed range. A total of
66 participants were classified as run-in failures because of metfor-
min intolerance prior to uptitration to the lowest targeted dose of
1000 mg/day.
The last patient last visit was planned for early April 2019,
followed by database lock in mid-May 2019. This manuscript, which
describes the SAP, was submitted for publication in parallel with the
last patient last visit and the planned database lock.
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2.2 | Baseline characteristics
Analysis of baseline characteristics was not included in the study pro-
tocol. However, as characterization of newly diagnosed T2DM
patients has been considered in recent years to provide valuable infor-
mation beyond the scientific study rationale, a post hoc analysis of
pooled, blinded key characteristics was performed and has been publi-
shed recently (Table 1).16 Participants were generally young and well
within the targeted glycaemic baseline range. Overall, the proportion
of men and women was equal in the study. The presence of early
microvascular complications was reported by 8% of the participants.
Mean baseline estimated glomerular filtration rate (eGFR), assessed
using the Modification of Diet in Renal Disease (MDRD) tool,17 indi-
catived normal renal function. The descriptive, blinded, country-level
demographics and baseline characteristics were provided to all 34 par-
ticipating countries and applicable regions for local publication.
3 | STATISTICAL ANALYSIS PLAN
3.1 | Primary endpoint and main analysis
The primary efficacy variable was time to confirmed initial treatment
failure. Initial treatment failure is defined as HbA1c ≥7.0% at two con-
secutive scheduled visits, three months apart. Time to confirmed ini-
tial treatment failure is defined as the time from randomization until
determination of the second of two consecutive HbA1c values ≥7.0%
after at least 13 weeks of treatment, that is, at the end of Period 1, in
line with the HbA1c target as defined by the main guidelines.18
Primary analysis concerning the primary efficacy variable will be per-
formed in the full analysis set (FAS) using a Cox proportional hazard
regression model with treatment approach and the pre-defined
geographic region as classification variables and baseline HbA1c as a co-
variate. It will also be performed in the per-protocol set (PPS) as a sup-
portive analysis (Table 2). Time to first treatment failure will be analysed
similarly, to support the results of primary analysis. All analyses will be car-
ried out at the one-sided 0.025 significance level (ie, two-sided 0.05).
3.2 | Sample size and statistical power
The planned sample size of 1000 per treatment approach will provide
approximately 75% power to detect a risk reduction of 25% (ie, a haz-
ard ratio of 0.75), with vildagliptin+metformin (vs metformin alone) as
the primary variable. An annual initial treatment failure rate of 7.1% in
the metformin monotherapy group is assumed,19 along with an annual
dropout rate of 4%, anticipated according to observations and data
from this study. Statistical power for the primary variable was
enhanced with two key modifications: (a) an expected lower dropout
rate of approximately 4%, vs 11% as originally assumed,19 and (b) one
primary efficacy variable, vs two as in the original plan. Over the
course of the study, smart and pragmatic inclusion of eligible partici-
pants with the ability to commit to the study for 5 years, based on an
effective retention plan and continuing support from committed study
site personnel, the final annualized discontinuation rate varied
between only 4% and 5%. For the final approach, a single primary var-
iable was adopted to optimize statistical power for the primary
F IGURE 1 VERIFY study design. bid, twice daily; d, day; ECG, electrocardiogram; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin;
ISR/G, insulin secretion rate over glucose; MET, metformin; VILDA, vildagliptin. aEarliest progression from Period 1 to Period 2 can be at Week
26, when second of the two consecutive HbA1c levels is ≥7.0%, determined after ≥13 weeks of treatment. bParticipants continuing to remain in
Period 1 without the two consecutive HbA1c levels ≥7.0% for the entire study period demonstrate durability of glycaemic control. Similarly, not
all participants will progress to Period 3 to receive insulin
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analysis, with no alpha adjustment needed for the two primary end-
points as in the original approach.
3.3 | Handling of missing data
In the analysis for the primary efficacy variable, patients discontinuing
the study for any reason during Period 1 were to be treated as censored
values at the time of discontinuation. Patients who remained under the
glycaemic threshold, or for whom a value above it was not confirmed at
the next scheduled visit, were to be censored at the time of last study
visit. No imputation will be made for missing HbA1c values when
assessing endpoints. Visits for which HbA1c values are available will be
used for assessment of the two consecutive visits for time to initial treat-
ment failure. However, imputation will be used to avoid missing values
for display of continuous variables, such as those for key secondary anal-
ysis parameters, as described below. For graphical presentation of contin-
uous variables, such as HbA1c and FPG over time, the last observation
carried forward (LOCF) approach has been used for systematic inclusion
of all time-points for these variables for all participants, if applicable.
Details of variable derivation are specified in the final SAP.
3.4 | Key secondary analyses
The rate of loss of glycaemic control over time will be estimated by an
annualized slope of HbA1c values from Week 26 to the end of Period
1. Data from Week 26 to the end of Period 1 will be analysed using a
linear mixed effect model, including treatment approach and geographic
regions as classification variables, baseline HbA1c and time (in years) of
HbA1c measurement as covariates and the interaction of treatment
approach by time. An unstructured covariance will be used in the linear
mixed effect model. The rationale for choosing the starting point for
estimating the rate (slope) of loss of glycaemic control over time is
based on previous observations,12 in which the maximal reduction in
mean HbA1c from baseline occurred between 24 and 32 weeks. Similar
analyses will be performed to determine the rate of loss in glycaemic
control from 26 weeks after study initiation until the end of Period 2.
Fasting plasma glucose (FPG) measurements at visits will be
assessed similarly to determine the rate of loss of glycaemic control
during the corresponding time periods. For those participants who
consented to undergo a standardized meal-test, as well as C-peptide
measurements at baseline, at 13 weeks and then annually, we will
determine changes in the area under the curve (AUC) of insulin secre-
tion rate over glucose (ISR/G), as an assessment of β-cell function, as
well as changes in oral glucose insulin sensitivity (OGIS).
Analysis data sets for secondary endpoints will include either FAS, for
variables for which all participants are observed over 5 years. For example,
FPG development during Period 2 is applicable only to those who entered
Period 2) and/or those who participated in the meal-test sub-study. All
secondary analyses, including those pre-specified in this SAP, will be of an
exploratory/descriptive nature andn thereforen no formal hypothesis test-
ing will be performed on these, in order to avoid multiplicity. As planned, a
statistical test for treatment comparison will be performed for each sec-
ondary endpoint using a pre-specified analysis model. Treatment differ-
ence, 95% confidence intervals and nominal P values are to be provided.
The nominal P values, without further adjustment, that are associated with
statistical assessment of the secondary analyses are provided as support-
ive evidence for scientific discussion and further hypothesis generation,
but not as a definite claim. The confidence intervals for treatment
estimates/differences will be useful in quantifying the expected treatment
effects for comparison between the two treatment groups.
3.5 | Supportive descriptive analyses
Absolute values and change in HbA1c from baseline will be summa-
rized descriptively by treatment approach and by visit up to the end
TABLE 1 Key demographics and baseline characteristics of
participants
Variable Total
Patient population, n 2001
Gender: women, n (%) 1060 (53.0)
Age, years
Median (IQR) 55 (48, 62)
Tertiles 51, 59
Race, n (%)
White European 1217 (60.8)
Black 49 (2.4)
Asian 373 (18.6)
Native American 210 (10.5)
Other 152 (7.6)
Duration of T2DM, months
Median (IQR) 3.4 (0.9, 10.3)
HbA1c, mmol/mol (%) 52 ± 3 (6.9 ± 0.3)
<7.0, n (%) 1423 (71.4)
≥7.0, n (%) 570 (28.6)
FPG, mmol/L 7.5 ± 1.5
Fasting insulin, median (IQR) (mU/L) 109 (75, 160)
HOMA-%β, median (IQR) (%) 84 (60, 116)
HOMA-%sensitivity, median (IQR) (%) 46 (31, 68)
BMI, kg/m2 31.1 ± 4.7
<30 kg/m2, n (%) 875 (43.7)
≥30 kg/m2, n (%) 1125 (56.3)
GFR (MDRD), mL min−1 1.73 m−2 87.4 ± 18.5
Metformin daily dose, mg 1597.3 ± 396.5
1000 mg, n (%) 520 (26.3)
1500 mg, n (%) 678 (33.9)
2000 mg, n (%) 796 (39.8)
Note: ± indicates standard deviation.
Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting
plasma glucose; GFR, glomerular filtration rate; HbA1c, glycated
haemoglobin; HOMA-β, homeostatic model assessment-%β; HOMA%
sensitivity homeostatic model assessment % sensitivity; IQR, interquartile
range; MDRD, modification of diet in renal disease; T2DM, type 2
diabetes mellitus.
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of Periods 1 and 2 and the end of study. Additionally, descriptive sub-
group analyses will be performed for primary and key secondary anal-
ysis based on pre-defined patient characteristics and other baseline
co-variates (Table 3). Other subgroups may be considered as needed.
3.6 | Exploratory analyses
Exploratory endpoints include time to insulin initiation and change in
body weight over time. HbA1c thresholds for failure and success will
be examined. Homeostatic model assessment will be used to assess
beta cell function (HOMA-B) and insulin resistance (HOMA-IR) will be
calculated as a function of glucose and insulin, using both the original
formula20 and the interactive iHOMA221 model. Implementation of
this model in the VERIFY study will be used to evaluate the impact of
study treatment strategies and to predict their effects on fasting glu-
cose, insulin, β-cell function and insulin sensitivity.
Changes in health status, determined using the EQ-5D ques-
tionnaire,22 will be assessed in conjunction with the selected
adverse events (AEs) and will be included in various health eco-
nomic modelling plans, especially for local assessment of the cost
effectiveness of combination therapy as compared to a stepwise
approach.
TABLE 3 Pre-planned sub-group analyses
Sub-group co-variates Definitions for analysis cut-off values
Baseline HbA1c category <7%, ≥7%
Baseline BMI <30 kg/m2, ≥30 kg/m2
Age per baseline tertiles of <51 years (n = 626), ≥59 years (n = 743)
Gender Male / female
Baseline smoking status Yes / no
Race White Caucasians, Asians, Hispanic Americans, etc.
Geographical regions Europe, Asia (with and without India), Latin America, Australia, South Africa
Associations between beta cell function and insulin resistance Based on assessment of HOMA-IR, HOMA-β / iHOMA-%β, iHOMA-% sensitivity
Other baseline demographics As appropriate
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessments for insulin resistance; HOMA-β,
homeostatic model assessment-%β; HOMA-β, homeostasis model assessments for β-cell function; HOMA% sensitivity homeostatic model assessment %
sensitivity.
TABLE 2 Analysis sets
Randomized analysis set
(RAN) and full analysis set (FAS)
RAN comprises all randomized patients and FAS comprises all randomized patients who received at least one
dose of randomized study medication (vildagliptin or placebo) and have at least one post-randomization
assessment of any efficacy parameter.
Intent-to-treat analysis (ITT) Following the ITT principle, data for participants will be analysed according to the treatment approach to which
they were assigned at randomization. Patients will not be excluded from ITT analysis based on protocol
deviations, including violations of study entry criteria concerning prior use of anti-diabetic agents and, eg,
BMI range.
Safety set (SAF) For assessment of safety, the SAF comprises all patients who received at least one dose of randomized study
medication (vildagliptin or placebo). Patients will be analysed according to the treatment approach received. If
a patient would have erroneously received, eg, both vildagliptin and placebo during Period 1, the patient will
be included in the vildagliptin group. NOTE: the SAF allows inclusion of non-randomized patients who
received the study drug in error, or those who did not tolerate up-titration of metformin and were thus
excluded from the study prior to randomization.
Per protocol set (PPS) PPS is a subset of FAS and comprises all randomized patients who received at least one dose of randomized
study medication (vildagliptin or placebo), who have undergone at least one post-randomization assessment
of any efficacy parameter during Period 1, who did not discontinue the study prior to week 26 (earliest
time-point for assessment of primary endpoint with consecutive, confirmed measurement of initial loss of
glycaemic control) and for whom there were no major protocol deviations as assessed prior to database lock
during Period 1.
Screened-only set (SCR) SCR comprises all patients who were screen-failed after the first visit or who entered the run-in phase but were
not randomized. No other analysis will be performed on this analysis set.
The number and percentage of patients in each analysis set will be summarized by treatment approach. The number and percentage of patients included in
the subgroup analyses, which required a separate consent at selected sites, concerning an opportunity to join the meal test, retinal micro-aneurysm count
and biomarker subsets (European patients only), will also be summarized by treatment approach. Meal test and retinal micro-aneurysm count data will be
presented as part of the efficacy evaluations. No summaries or analyses will be created for biomarker data as part of this analysis plan, as the samples,
drawn after receipt of a separate consent, are part of a pivotal consortium initiative for assessment of drug-induced liver toxicity in a European population.
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In a subgroup of patients, change in retinal micro-aneurysm count
from baseline to Years 4 and 5 will be assessed by independent, cen-
tral reading, based on a pre-defined protocol. Microvascular and
macrovascular complications will be descriptively reported, includ-
ing summaries of microalbuminuria, progression to renal insuffi-
ciency and all-cause mortality. For secondary and exploratory
endpoints, the time-to-event variables will be analysed using a Cox
proportional hazard model similar to that used for the primary vari-
able; the rate of loss in respective variables will be analysed using a
linear mixed effect model; the variables for change from baseline
will be evaluated by an analysis of covariance (ANCOVA), with
treatment approach and geographic region as classification factors
and baseline as a covariate.
3.7 | Avoiding bias
Pre-planned protection against risk of bias or confounding has been
essential in the design of the VERIFY study. Mitigation of and
attempts to minimize bias is achieved by optimization of the study
design through randomization and blinding, through inclusion/exclu-
sion criteria to avoid selection bias, through a robust retention plan to
detect bias for true effect or outcomes, and through intention-to-treat
analysis. Public submission of a detailed SAP is a key component to
avoid occurrence of post-hoc data selection or selective reporting and,
ultimately, publication bias.
The VERIFY study included patients who reflective the current,
rather variable T2DM management standards. In order to avoid
measurement or analytical bias, all samples were tranferred for anal-
ysis to an accredited central laboratory, to confirm eligibility, and
also to determine all key variables. The eligibility criteria ensured
inclusion of a wide range of newly diagnosed patients, ensuring that
their glycaemic parameters were within the anticipated range and
that changes in glycaemia, the main endpoint, was not influenced by
concomitant disease(s) or management thereof. Initially, based on
previous studies in newly diagnosed patients,19 albeit in a less
diverse population, the rate of premature discontinuation was antici-
pated to be significantly higher. Considerable efforts have been
made to maximize the completeness of study participation via an
effective retention programme, to avoid under-estimation of the
true effects of treatment strategies on most outcomes, while the
likely impact can be quantified and the direction of the effect is
known, for the most part. However, sensitivity analyses will be per-
formed as well. For example, the first occurrence of the initial loss of
glycaemic control will be used to eliminate the bias induced by
knowledge of the progressive glycaemic change or by the impact of
clinical reality. It must be acknowledged that longitudinal changes, in
body weight for example, might introduce an unintentional con-
founding effect. Therefore, a robust analysis of the role of the inde-
pendent determinants that drive the primary response will be
undertaken as part of a post hoc data interrogation, in addition to
this pre-planned SAP. Results will be reported in accordance with
CONSORT guidelines for cohort studies23 and will be submitted for
publication in a peer-reviewed journal.
4 | FOCUS ON SAFETY AND EXPLORATION
OF ADJUDICATING CARDIOVASCULAR
ENDPOINTS
An integrated analysis of safety and tolerability will compare the two
treatment strategies during the five-year treatment periods in the safety
data set (SAF). Key safety variables (overall AEs, serious AEs, AEs lead-
ing to study drug discontinuation or interruption, incidence of
hypoglycaemia, predefined AE risks of interest) will also be summarized
by treatment approach and expectations (Table 4). SAEs will be grouped
into major categories, defined by the latest Medical Dictionary for Reg-
ulatory Activities version 21.1 (MedDRA).24 The incidence of
treatment-emergent AEs will be summarized by primary system organ
class, preferred term, severity and relationship to study drug. Evaluation
of clinical laboratory test results and vital signs will be undertaken only
at scheduled study visits, while any laboratory abnormalities necessitat-
ing treatment or meeting a clinically significant change will be captured
on the database as an AE and included in AE summary tables/listings.





4. Haematology: RBC (total), WBC (total), platelet count (direct),
haemoglobin, haematocrit, basophils (absolute, %), eosinophils
(absolute, %), lymphocytes (absolute, %), monocytes (absolute, %),
neutrophils (absolute, %)
5. Blood chemistry: ALT, albumin, alkaline phosphatase, AST,
bilirubin (direct), bilirubin (total), blood urea nitrogen, calcium
(total), chloride, high-sensitivity c-reactive protein,
phosphocreatine kinase (CPK), creatinine kinase muscle-brain-type
isoenzyme if CPK elevated, creatinine, γ-glutamyl transferase,
GFR via MDRD formula, lactate dehydrogenase, potassium,
protein (total), sodium, uric acid
6. Urine tests: blood, glucose, ketones, leukocytes, pH, protein,
pregnancy (β-hCG), urine albumin/creatinine ratio




10. Incidence of hypoglycaemia events
11. All treatment-emergent AEs/SAEs
12. New or progression of existing microvascular and macrovascular
complications (reported as AEs), new onset microalbuminuria,
progression to renal insufficiency (eGFR <60 mL min−1 1.73 m−2)
or doubling of serum creatinine to at least 200 μM (2.26 mg/dL)
and all-cause mortality, to assess the overall complications event
rate during the study
Abbreviations: AE, adverse events; ALT, Alanine aminotransferase; AST,
aspartate aminotransferase; eGFR, estimated glomerular filtration rate;
hCG, human chorionic gonadotropin; MDRD, modification of diet in renal
disease; RBC, red blood cells; SAE, serious AE; WBC, white blood cells.
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Hypoglycaemic events (HEs) (<3.0 mmol/L [<54 mg/dL])25 will be
characterized by event profile, such as ability to self-treat and self-
monitor plasma glucose level, precipitating event, time from last meal,
time from last dose and time of day. The incidence of HEs and asymp-
tomatic low blood glucose that was entered in the glycaemia study
diary and met the criteria for those reporting at least one HE and for
those who discontinued following HEs or who reported confirmed or
suspected grade 2 events will be summarized by numbers and per-
centages for each treatment approach. The summary will be repeated
according to pre-defined age groups and any other cut-offs as
deemed appropriate after unblinding. Kaplan–Meier analyses will be
used if the numbers are sufficient to warrant the approach.
Overall microvascular and macrovascular complications will be
assessed separately by treatment approach. Overall complications are
defined as new or progression of existing microvascular and
macrovascular complications, confirmed by adjudication, new-onset
microalbuminuria, progression to renal insufficiency (eGFR
<60 mL min−1 1.73 m−2) or doubling of serum creatinine to at least
200 μM (2.26 mg/dL) and all-cause mortality. The frequency and per-
centage of patients experiencing each complication will be summarized.
5 | CHANGES TO THE ORIGINAL SAP
For long-term interventional studies, the SAP must be critically
reviewed and updated as necessary prior to unblinding and data anal-
ysis. The reason for updates, such as baseline characteristics that
drove the pre-planned sub-analyses in a previously unpredictable
direction, will be clearly documented in the SAP to ensure transpar-
ency and external validity of the study.26
The original SAP for the VERIFY study was created based on the
initial study protocol and related planned analyses, and it was
updated/refined prior to completion of data collection and database
lock. Key changes to the study protocol and/or SAP since the first
version included additional clarification concerning a contraindication
to treatment with metformin or vildagliptin. At the same time, a new
inclusion criterion was added, based on health authority recommenda-
tions to ensure that only patients who received appropriate advice
concerning lifestyle modification prior to enrolment, including diet
counselling and exercise training, may be included. However, the main
amendment to the protocol involved inclusion of a CV adjudication
committee and an independent data monitoring committee. In the
context of that amendment, additional dose-adjustment schedules
and the addition of serum C-peptide measurement as a standard
chemistry assessment were introduced for all patients.
Since the study commenced, it was decided to explore the blinded
baseline characteristics as a post-hoc analysis as this was not pre-
specified in the study protocol. Additionally, the SAP was refined to
reflect an updated understanding of the main analysis approach by
introducing only one primary efficacy endpoint. As the probability and
risk of time to initial loss of glycaemic control as the primary efficacy
variable will be presented as a hazard ratio and failure rate over time,
the statistical approach and power calculations, including the impact
of the known retention, were updated accordingly, while assessment
of the rate of loss of glycaemic control by an annualized slope of mean
HbA1c over time from Week 26 to the end of Period 1 was desig-
nated, rather, as a key secondary analysis. Based on the now known
baseline characteristics, the originally suggested sub-analyses have
been modified to reflect the actual population with respect to distri-
bution of age, weight and BMI categories.
6 | CONCLUSIONS
According to optimum trial practice, details of the statistical analysis
and data handling plan prior to locking the VERIFY study database are
reported here. This plan is coherent with the high quality standards of
internal validity to minimize analysis bias, and will enhance the clinical
utility of reported results, aiming to improve early treatment and lead-
ing to more optimized outcomes in the management of patients with
newly diagnosed T2DM.
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